Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARTHA HERNANDEZ ILLAS

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1972517464
CMS profile
733063
Location
FORT LAUDERDALE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$163.00

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $163.00 4

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Amgen Inc. $125.00 1
PFIZER INC. $38.00 3

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARTHA HERNANDEZ ILLAS

NPI 1972517464 · CMS profile ID 733063

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

FORT LAUDERDALE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1972517464?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARTHA HERNANDEZ ILLAS, NPI 1972517464, CMS profile ID 733063. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1972517464?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). MARTHA HERNANDEZ ILLAS, NPI 1972517464, CMS profile ID 733063. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1972517464?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
MARTHA HERNANDEZ ILLAS, NPI 1972517464, CMS profile ID 733063, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1972517464?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $163.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $15.4609/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672777395 CMS
Amgen Inc. $125.0008/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662726285 CMS
PFIZER INC. $6.7503/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672054747 CMS
PFIZER INC. $15.7901/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672016437 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $163.00 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019
Generated from
OP_DTL_GNRL_PGYR2019_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,780,360.32 3
PY2024 Principal investigator $1,857,594.44 9
PY2023 Principal investigator $2,411,538.38 25
PY2022 Recipient $8,492.00 4
PY2022 Principal investigator $6,968,480.90 32
PY2021 Principal investigator $4,588,067.03 55
PY2020 Recipient $1,800.00 2
PY2020 Principal investigator $1,389,670.25 53
PY2019 Principal investigator $5,017,814.30 57

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

55 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $251,187.90 12/31/2021 Non-covered Recipient Entity
QPS MIAMI RESEARCH ASSOCIATES
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-RangingTrial to Evaluate the Safety and Immunogenicity of V590 in Healthy Adults No dispute reported 06/30/2026 848738949
Principal investigator 1 Merck Sharp & Dohme Corporation $42.00 12/31/2021 Non-covered Recipient Entity
QPS MRA, LLC EARLY PHASE
An Open-Label, Single-Dose, 3-Period, Fixed Sequence Study to Determine the Effect of Food and a Proton Pump Inhibitor on Gefapixant MK-7264 F04B Pharmacokinetics in Healthy Participants. No dispute reported 06/30/2026 848754213
Principal investigator 1 Merck Sharp & Dohme Corporation $729.60 12/31/2021 Non-covered Recipient Entity
QPS MRA, LLC EARLY PHASE
A Two-Period Study to Evaluate the Effects of Multiple Oral Doses of Itraconazole on the Single-Dose Pharmacokinetics of MK-8189 in Healthy Participants No dispute reported 06/30/2026 848756915
Principal investigator 1 Merck Sharp & Dohme Corporation $72.46 12/31/2021 Non-covered Recipient Entity
QPS MRA, LLC EARLY PHASE
A Two-Period Study to Evaluate the Effects of Multiple Oral Doses of Itraconazole on the Single-Dose Pharmacokinetics of MK-8189 in Healthy Participants No dispute reported 06/30/2026 848756917
Principal investigator 1 PFIZER INC. $242,814.50 12/23/2021 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 OPEN LABEL FIXED SEQUENCE STUDY TO ESTIMATE THE EFFECT OF MULTIPLE DOSE PF06650833 ON THE PHARMACOKINETICS OF SINGLE DOSE ORAL CONTRACEPTIVE STEROIDS IN HEALTHY FEMALE PARTICIPANTS No dispute reported 06/30/2026 832551817
Principal investigator 1 PFIZER INC. $20,460.72 12/16/2021 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 832586513
Principal investigator 1 Noven Pharmaceuticals, Inc. $83,756.81 12/09/2021 Non-covered Recipient Entity
QPS MRA LLC
A PHASE I STUDY TO ASSESS SKIN IRRITATION AND SENSITIZATION OF HP-1050 TRANSDERMAL SYSTEM COMPARED TO XULANE IN HEALTHY ADULT FEMALES No dispute reported 06/30/2026 831015013
Principal investigator 1 PFIZER INC. $250.00 12/08/2021 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED FIRSTINHUMAN STUDY TO EVALUATE THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF PF07258669 ADMINISTERED TO HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 832551827
Principal investigator 1 Amgen Inc. $220,720.00 11/27/2021 Non-covered Recipient Entity
QPS MIAMI RESEARCH ASSOCIATES
AMG 598 - Ph 1 Safety; Tolerability; PK and PD of MAD No dispute reported 06/30/2026 830980001
Principal investigator 1 PFIZER INC. $58,980.50 11/23/2021 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 OPEN LABEL FIXED SEQUENCE STUDY TO ESTIMATE THE EFFECT OF MULTIPLE DOSE PF06650833 ON THE PHARMACOKINETICS OF SINGLE DOSE ORAL CONTRACEPTIVE STEROIDS IN HEALTHY FEMALE PARTICIPANTS No dispute reported 06/30/2026 832551715
Principal investigator 1 PFIZER INC. $4,510.00 11/16/2021 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE ESCALATING ORAL DOSES OF PF07081532 IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 832766655
Principal investigator 1 Noven Pharmaceuticals, Inc. $2,520.00 11/04/2021 Non-covered Recipient Entity
QPS MRA LLC
A PHASE I STUDY TO ASSESS SKIN IRRITATION AND SENSITIZATION OF HP-1050 TRANSDERMAL SYSTEM COMPARED TO XULANE IN HEALTHY ADULT FEMALES No dispute reported 06/30/2026 831014972
Principal investigator 1 Noven Pharmaceuticals, Inc. $92,344.21 11/04/2021 Non-covered Recipient Entity
QPS MRA LLC
A PHASE I STUDY TO ASSESS SKIN IRRITATION AND SENSITIZATION OF HP-1050 TRANSDERMAL SYSTEM COMPARED TO XULANE IN HEALTHY ADULT FEMALES No dispute reported 06/30/2026 831014977
Principal investigator 1 H. Lundbeck A S $26,161.42 11/03/2021 Non-covered Recipient Entity
QPS MRA LLC
Interventional, randomised, double-blind, placebo-controlled, single-ascending-dose study investigating safety, PK and PD in healthy young and elderly subjects No dispute reported 06/30/2026 1179406072
Principal investigator 1 PFIZER INC. $17,607.33 10/29/2021 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE ESCALATING ORAL DOSES OF PF07081532 IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 832843299
Principal investigator 1 PFIZER INC. $85,934.00 10/08/2021 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED FIRSTINHUMAN STUDY TO EVALUATE THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF PF07258669 ADMINISTERED TO HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 832551537
Principal investigator 1 Noven Pharmaceuticals, Inc. $93,036.67 10/01/2021 Non-covered Recipient Entity
QPS MRA LLC
A PHASE I STUDY TO ASSESS SKIN IRRITATION AND SENSITIZATION OF HP-1050 TRANSDERMAL SYSTEM COMPARED TO XULANE IN HEALTHY ADULT FEMALES No dispute reported 06/30/2026 831014951
Principal investigator 1 PFIZER INC. $20,460.72 09/29/2021 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 832809559
Principal investigator 1 H. Lundbeck A S $1,325.00 09/09/2021 Non-covered Recipient Entity
QPS MRA LLC
Interventional, randomised, double-blind, placebo-controlled, single-ascending-dose study investigating safety, PK and PD in healthy young and elderly subjects No dispute reported 06/30/2026 1179405908
Principal investigator 1 H. Lundbeck A S $16,097.88 09/09/2021 Non-covered Recipient Entity
QPS MRA LLC
Interventional, randomised, double-blind, placebo-controlled, single-ascending-dose study investigating safety, PK and PD in healthy young and elderly subjects No dispute reported 06/30/2026 1179405910
Principal investigator 1 H. Lundbeck A S $17,670.77 09/09/2021 Non-covered Recipient Entity
QPS MRA LLC
Interventional, randomised, double-blind, placebo-controlled, single-ascending-dose study investigating safety, PK and PD in healthy young and elderly subjects No dispute reported 06/30/2026 1179405912
Principal investigator 1 H. Lundbeck A S $20,846.21 09/09/2021 Non-covered Recipient Entity
QPS MRA LLC
Interventional, randomised, double-blind, placebo-controlled, single-ascending-dose study investigating safety, PK and PD in healthy young and elderly subjects No dispute reported 06/30/2026 1179405914
Principal investigator 1 H. Lundbeck A S $3,213.61 09/09/2021 Non-covered Recipient Entity
QPS MRA LLC
Interventional, randomised, double-blind, placebo-controlled, single-ascending-dose study investigating safety, PK and PD in healthy young and elderly subjects No dispute reported 06/30/2026 1179405916
Principal investigator 1 H. Lundbeck A S $325.00 09/09/2021 Non-covered Recipient Entity
QPS MRA LLC
Interventional, randomised, double-blind, placebo-controlled, single-ascending-dose study investigating safety, PK and PD in healthy young and elderly subjects No dispute reported 06/30/2026 1179405918
Principal investigator 1 H. Lundbeck A S $8,890.83 09/09/2021 Non-covered Recipient Entity
QPS MRA LLC
Interventional, randomised, double-blind, placebo-controlled, single-ascending-dose study investigating safety, PK and PD in healthy young and elderly subjects No dispute reported 06/30/2026 1179405920
Principal investigator 1 PFIZER INC. $540,450.00 09/04/2021 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE ESCALATING ORAL DOSES OF PF07081532 IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 832814567
Principal investigator 1 PFIZER INC. $688,805.00 09/03/2021 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE ESCALATING ORAL DOSES OF PF07081532 IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 832708089
Principal investigator 1 Noven Pharmaceuticals, Inc. $69,629.60 09/02/2021 Non-covered Recipient Entity
QPS MRA LLC
A PHASE I STUDY TO ASSESS SKIN IRRITATION AND SENSITIZATION OF HP-1050 TRANSDERMAL SYSTEM COMPARED TO XULANE IN HEALTHY ADULT FEMALES No dispute reported 06/30/2026 831014499
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $602.10 08/24/2021 Non-covered Recipient Entity
MIAMI RESEARCH ASSOCIATES LLC
A PHASE 2, LONG-TERM IMMUNOGENICITY FOLLOW-UP TRIAL OF ADULT AND ELDERLY SUBJECTS WHO HAVE PREVIOUSLY RECEIVED AN INTRAMUSCULAR INJECTION OF NOROVIRUS GI.1/GII.4 BIVALENT VIRUS-LIKE PARTICLE VACCINE No dispute reported 06/30/2026 816755109
Principal investigator 1 PFIZER INC. $160,834.00 08/06/2021 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED FIRSTINHUMAN STUDY TO EVALUATE THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF PF07258669 ADMINISTERED TO HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 832551705
Principal investigator 1 Noven Pharmaceuticals, Inc. $45,208.75 07/29/2021 Non-covered Recipient Entity
QPS MRA LLC
A PHASE I STUDY TO ASSESS SKIN IRRITATION AND SENSITIZATION OF HP-1050 TRANSDERMAL SYSTEM COMPARED TO XULANE IN HEALTHY ADULT FEMALES No dispute reported 06/30/2026 831014045
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $602.10 07/16/2021 Non-covered Recipient Entity
MIAMI RESEARCH ASSOCIATES LLC
A PHASE 2, LONG-TERM IMMUNOGENICITY FOLLOW-UP TRIAL OF ADULT AND ELDERLY SUBJECTS WHO HAVE PREVIOUSLY RECEIVED AN INTRAMUSCULAR INJECTION OF NOROVIRUS GI.1/GII.4 BIVALENT VIRUS-LIKE PARTICLE VACCINE No dispute reported 06/30/2026 816741971
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $14,709.00 07/13/2021 Non-covered Recipient Entity
MIAMI RESEARCH ASSOCIATES
A PHASE 1, RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED, SAFETY, IMMUNOGENICITY, AND DOSE RANGING STUDY OF PURIFIED INACTIVATED ZIKA VIRUS VACCINE (PIZV) CANDIDATE IN FLAVIVIRUS NA?VE AND PRIMED HEALTHY ADULTS AGED 18 TO 49 YEARS No dispute reported 06/30/2026 816740137
Principal investigator 1 PFIZER INC. $291,094.05 07/09/2021 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED FIRSTINHUMAN STUDY TO EVALUATE THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF PF07258669 ADMINISTERED TO HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 832551611
Principal investigator 1 Noven Pharmaceuticals, Inc. $3,851.24 07/01/2021 Non-covered Recipient Entity
QPS MRA LLC
A PHASE I STUDY TO ASSESS SKIN IRRITATION AND SENSITIZATION OF HP-1050 TRANSDERMAL SYSTEM COMPARED TO XULANE IN HEALTHY ADULT FEMALES No dispute reported 06/30/2026 831011867
Principal investigator 1 PFIZER INC. $45,500.00 06/16/2021 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE ESCALATING ORAL DOSES OF PF07081532 IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 832733967
Principal investigator 1 PFIZER INC. $315,567.14 06/05/2021 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED FIRSTINHUMAN STUDY TO EVALUATE THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF PF07258669 ADMINISTERED TO HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 832551547
Principal investigator 1 Noven Pharmaceuticals, Inc. $21,116.23 06/03/2021 Non-covered Recipient Entity
QPS MRA LLC
A PHASE I STUDY TO ASSESS SKIN IRRITATION AND SENSITIZATION OF HP-1050 TRANSDERMAL SYSTEM COMPARED TO XULANE IN HEALTHY ADULT FEMALES No dispute reported 06/30/2026 831011691
Principal investigator 1 PFIZER INC. $229,827.32 05/21/2021 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED FIRSTINHUMAN STUDY TO EVALUATE THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF PF07258669 ADMINISTERED TO HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 832551619
Principal investigator 1 PFIZER INC. $25,000.00 05/21/2021 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE ESCALATING ORAL DOSES OF PF07081532 IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 832856359
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,429.00 05/04/2021 Non-covered Recipient Entity
MIAMI RESEARCH ASSOCIATES
A PHASE 1, RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED, SAFETY, IMMUNOGENICITY, AND DOSE RANGING STUDY OF PURIFIED INACTIVATED ZIKA VIRUS VACCINE (PIZV) CANDIDATE IN FLAVIVIRUS NA?VE AND PRIMED HEALTHY ADULTS AGED 18 TO 49 YEARS No dispute reported 06/30/2026 816719463
Principal investigator 1 Noven Pharmaceuticals, Inc. $74,372.09 05/03/2021 Non-covered Recipient Entity
QPS MRA LLC
A PHASE I STUDY TO ASSESS SKIN IRRITATION AND SENSITIZATION OF HP-1050 TRANSDERMAL SYSTEM COMPARED TO XULANE IN HEALTHY ADULT FEMALES No dispute reported 06/30/2026 831011441
Principal investigator 1 PFIZER INC. $28,768.55 04/06/2021 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED FIRSTINHUMAN STUDY TO EVALUATE THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF PF07258669 ADMINISTERED TO HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 832551527
Principal investigator 1 Noven Pharmaceuticals, Inc. $183,052.00 04/01/2021 Non-covered Recipient Entity
BIO KINETIC CLINICAL
A PHASE I STUDY TO ASSESS SKIN IRRITATION AND SENSITIZATION OF HP-1050 TRANSDERMAL SYSTEM COMPARED TO XULANE IN HEALTHY ADULT FEMALES No dispute reported 06/30/2026 831011201
Principal investigator 1 Noven Pharmaceuticals, Inc. $104,077.30 03/25/2021 Non-covered Recipient Entity
QPS MRA LLC
A PHASE I STUDY TO ASSESS SKIN IRRITATION AND SENSITIZATION OF HP-1050 TRANSDERMAL SYSTEM COMPARED TO XULANE IN HEALTHY ADULT FEMALES No dispute reported 06/30/2026 831011141
Principal investigator 1 Noven Pharmaceuticals, Inc. $44,057.78 02/25/2021 Non-covered Recipient Entity
QPS MRA LLC
A PHASE I STUDY TO ASSESS SKIN IRRITATION AND SENSITIZATION OF HP-1050 TRANSDERMAL SYSTEM COMPARED TO XULANE IN HEALTHY ADULT FEMALES No dispute reported 06/30/2026 831010963
Principal investigator 1 Amgen Inc. $4,275.00 02/23/2021 Non-covered Recipient Entity
QPS MIAMI RESEARCH ASSOCIATES
AMG 890_FIH/ SAD No dispute reported 06/30/2026 830980263
Principal investigator 1 PFIZER INC. $157,024.00 02/23/2021 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE ESCALATING ORAL DOSES OF PF07081532 IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 832719433
Principal investigator 1 PFIZER INC. $14,425.00 02/05/2021 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE ESCALATING ORAL DOSES OF PF07081532 IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 832758597
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1.94 02/04/2021 Non-covered Recipient Entity
QPS MRA LLC
A RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF REGN5069 IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 793093919
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,345.90 02/04/2021 Non-covered Recipient Entity
QPS MRA LLC
A RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF REGN5069 IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 793093921
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $766.80 01/26/2021 Non-covered Recipient Entity
MIAMI RESEARCH ASSOCIATES
A PHASE 1, RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED, SAFETY, IMMUNOGENICITY, AND DOSE RANGING STUDY OF PURIFIED INACTIVATED ZIKA VIRUS VACCINE (PIZV) CANDIDATE IN FLAVIVIRUS NA?VE AND PRIMED HEALTHY ADULTS AGED 18 TO 49 YEARS No dispute reported 06/30/2026 816685513
Principal investigator 1 PFIZER INC. $1,898.00 01/16/2021 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE ESCALATING ORAL DOSES OF PF07081532 IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 832755839
Principal investigator 1 Noven Pharmaceuticals, Inc. $37,500.00 01/14/2021 Non-covered Recipient Entity
QPS MRA LLC
A PHASE I STUDY TO ASSESS SKIN IRRITATION AND SENSITIZATION OF HP-1050 TRANSDERMAL SYSTEM COMPARED TO XULANE IN HEALTHY ADULT FEMALES No dispute reported 06/30/2026 831010796
Principal investigator 1 PFIZER INC. $189,319.00 01/12/2021 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE ESCALATING ORAL DOSES OF PF07081532 IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 832727003